2026 ICD-10-CM Diagnosis Code C88.30Immunoproliferative small intestinal disease not having achieved remission
ICD-10-CM Codes›C00–D49›C81-C96›C88
- Billable — Valid for Submission
- Chronic Condition
C88.30 is a billable ICD-10-CM diagnosis code for immunoproliferative small intestinal disease not having achieved remission. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 820 through 825, 840 through 842. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Non-Hodgkin lymphoma.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Alpha heavy chain disease
- Alpha heavy chain disease, enteric form
- Alpha heavy chain disease, respiratory form
- Heavy chain disease
- Immunoproliferative small intestinal disease
- Monoclonal abnormal heavy chain protein devoid of light chains detected
- Monoclonal alpha heavy chain detected
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Alpha heavy chain disease NOS
- Alpha heavy chain disease not having achieved remission
- Alpha heavy chain disease with failed remission
- Immunoproliferative small intestinal disease NOS
- Immunoproliferative small intestinal disease with failed remission
- Mediterranean lymphoma NOS
- Mediterranean lymphoma not having achieved remission
- Mediterranean lymphoma with failed remission
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Immunoproliferative Small Intestinal Disease
a condition that is caused by hyperplasia of lymphocytes in the small intestine (intestine, small) and the mesenteric lymph nodes. these lymphocytes produce an anomalous alpha heavy chain protein. generally, these ipsid patients have either concurrent lymphoma or develop lymphoma within a few years. the disease was first described in the mediterranean region and is characterized by malabsorption; weight loss; diarrhea; and steatorrhea.Heavy Chain Disease
a disorder of immunoglobulin synthesis in which large quantities of abnormal heavy chains are excreted in the urine. the amino acid sequences of the n-(amino-) terminal regions of these chains are normal, but they have a deletion extending from part of the variable domain through the first domain of the constant region, so that they cannot form cross-links to the light chains. the defect arises through faulty coupling of the variable (v) and constant (c) region genes.
Code History & ChangesHistory
Replacement C88.30 replaces the following previously assigned code(s):
- C88.3 - Immunoproliferative small intestinal disease
Questions About C88.30Overview
Is C88.30 (Immunoproliferative small intestinal disease) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report immunoproliferative small intestinal disease not having achieved remission on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C88.30 group to?
When immunoproliferative small intestinal disease not having achieved remission is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, with relative weights from 1.0104 to 5.8648 depending on complications. Higher weights mean higher Medicare reimbursement.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
